Your browser doesn't support javascript.
loading
Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.
Kim, Soo Han; Jo, Eun Jung; Mok, Jeongha; Lee, Kwangha; Kim, Ki Uk; Park, Hye-Kyung; Lee, Min Ki; Eom, Jung Seop; Kim, Mi-Hyun.
Afiliación
  • Kim SH; Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
  • Jo EJ; Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
  • Mok J; Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
  • Lee K; Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
  • Kim KU; Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
  • Park HK; Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
  • Lee MK; Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
  • Eom JS; Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
  • Kim MH; Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Korean J Intern Med ; 38(2): 218-225, 2023 03.
Article en En | MEDLINE | ID: mdl-36800677
BACKGROUND/AIMS: Despite the obvious benefits of adding immune checkpoint inhibitors to platinum-etoposide chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC), real-world data remain scarce. METHODS: This retrospective study included 89 patients with ES-SCLC treated with platinum-etoposide chemotherapy alone (chemo-only group; n = 48) or in combination with atezolizumab (atezolizumab group; n = 41) and compared the survival outcomes between these two groups. RESULTS: Overall survival (OS) was significantly longer in the atezolizumab group than in the chemo-only group (15.2 months vs. 8.5 months; p = 0.047), whereas the median progression-free survival was almost the same (5.1 months vs. 5.0 months) in both groups (p = 0.754). Subsequent multivariate analysis revealed that thoracic radiation (hazard ratio [HR], 0.223; 95% confidence interval [CI], 0.092-0.537; p = 0.001) and atezolizumab administration (HR, 0.350; 95% CI, 0.184-0.668; p = 0.001) were favorable prognostic factors for OS. In the thoracic radiation subgroup, patients who received atezolizumab demonstrated favorable survival outcomes and no grade 3-4 adverse events (AEs). CONCLUSION: The addition of atezolizumab to platinum-etoposide resulted in favorable outcomes in this real-world study. Thoracic radiation was associated with improved OS and acceptable AE risk in combination with immunotherapy in patients with ES-SCLC.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Pulmonar de Células Pequeñas / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Korean J Intern Med Asunto de la revista: MEDICINA INTERNA Año: 2023 Tipo del documento: Article Pais de publicación: Corea del Sur
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Pulmonar de Células Pequeñas / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Korean J Intern Med Asunto de la revista: MEDICINA INTERNA Año: 2023 Tipo del documento: Article Pais de publicación: Corea del Sur